InVivo Therapeutics Holdings Insiders
NVIVDelisted Stock | USD 1.38 0.07 5.34% |
InVivo Therapeutics employs about 6 people. The company is managed by 10 executives with a total tenure of roughly 11 years, averaging almost 1.0 years of service per executive, having 0.6 employees per reported executive. Recap of InVivo Therapeutics' management performance can provide insight into the venture performance.
InVivo |
InVivo Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.5371) % which means that it has lost $0.5371 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9811) %, meaning that it created substantial loss on money invested by shareholders. InVivo Therapeutics' management efficiency ratios could be used to measure how well InVivo Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.InVivo Therapeutics Workforce Comparison
InVivo Therapeutics Holdings is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 799. InVivo Therapeutics maintains roughly 6.0 in number of employees contributing less than 1% to equities under Health Care industry.
InVivo Therapeutics Notable Stakeholders
An InVivo Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as InVivo Therapeutics often face trade-offs trying to please all of them. InVivo Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting InVivo Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Joseph MD | CoFounder | Profile | |
Dr Langer | CoFounder Board | Profile | |
Richard MD | CEO and Presidentident | Profile | |
Richard Christopher | CFO, Treasurer | Profile | |
Jerome Gangitano | VP Operations | Profile | |
MD FACP | Consultant | Profile | |
Heather JD | Chief Counsel | Profile | |
Richard Toselli | Chief Medical Officer | Profile | |
Joseph Vacanti | CoFounder | Profile |
About InVivo Therapeutics Management Performance
The success or failure of an entity such as InVivo Therapeutics often depends on how effective the management is. InVivo Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of InVivo management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the InVivo management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries . The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. Invivo Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 7 people.
Please note, the imprecision that can be found in InVivo Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of InVivo Therapeutics Holdings. Check InVivo Therapeutics' Beneish M Score to see the likelihood of InVivo Therapeutics' management manipulating its earnings.
InVivo Therapeutics Workforce Analysis
Traditionally, organizations such as InVivo Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare InVivo Therapeutics within its industry.InVivo Therapeutics Manpower Efficiency
Return on InVivo Therapeutics Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 1.6M | |
Net Loss Per Executive | 932.7K | |
Working Capital Per Employee | 2.5M | |
Working Capital Per Executive | 1.5M |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Other Consideration for investing in InVivo Stock
If you are still planning to invest in InVivo Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the InVivo Therapeutics' history and understand the potential risks before investing.
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |